[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Procare Health Iberia S.L.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100601028","evaluation-of-adherence-with-bisphosphonates-and-calcium-and-vitamin-d-supplements-in-women-with-postmenopausal-osteoporosis-100601028",false,"NCT07105163","Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis","Observational, Cross-sectional, Multicenter Study to Evaluate Adherence to Different Treatment Regimens With Oral Bisphosphonates and Calcium and Vitamin D Supplements in Postmenopausal Osteoporosis.","OSTEOAD","Inclusion Criteria:\n\n1. \\- Women diagnosed with postmenopausal OP.\n2. \\- Women who had been prescribed oral treatment with a BP administered monthly or weekly together with a Ca\u002FD supplement (sachets or chewable tablets) administered daily, at least 6 months prior to inclusion in the study.\n3. \\- Women who had given their written informed consent before participating in the study.\n\nExclusion Criteria:\n\nNone","FEMALE",{"count":19,"type":20},480,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis. The study will consist of a single visit that will coincide with one of the patient's usual follow-up visits according to standard clinical practice. During this visit, information will be collected from the patient's medical history and an interview will be conducted using 3 questionnaires to assess how and how often the patient takes the treatment, possible forgetfulness, and whether or not the patient is satisfied with their current treatment.",[24],"Post Menopausal Osteoporosis",[26,27,28,29,30,31],"Procare","Post menopausal osteoporosis","Bisphosphonate","calcium","vitamin D","supplement","RECRUITING","2025-07-29",{"date":35,"type":36},"2025-08-05","ACTUAL",{"date":38,"type":36},"2025-03-03",{"date":40,"type":20},"2025-12",{"name":42,"class":43},"Procare Health Iberia S.L.","INDUSTRY",21,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100599400","observational-study-to-evaluate-fertility-in-women-between-32-and-38-years-old-treated-with-the-ovosicare-fertility-100599400","NCT07083999","Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility","Prospective Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility Food Supplement Containing a Combination of MYO\u002FDCI in a 3.6:1 Ratio, Antioxidants, Vitamins and Minerals","FERTILOBS","Inclusion Criteria:\n\n1. \\- Women who agree to participate in the study by signing the informed consent.\n2. \\- Between 32 and 38 years old.\n3. \\- Who come to doctor´s office stating that they have been trying to get pregnant for at least 6 months.\n\nExclusion Criteria:\n\n1. \\- BMI \\> 30 kg\u002Fm2.\n2. \\- Existence of severe male factor subfertility according to the criteria of the World Health Organization (WHO), with at least one analysis obtained in the last 6 months with one or more variables with values of:\n\n   * Azoospermia\n   * Progressive motility \\\u003C25%\n   * Normal morphology ≤2%\n3. \\- Pregnant or breastfeeding women.\n4. \\- Patients with type 1 diabetes or thyroid disease.\n5. \\- Patients with any assisted reproduction technique scheduled during the duration of the study.\n6. \\- Patients who have used or taken systemic steroids, anticonvulsants, antiretroviral treatment for HIV or hepatitis B in the last month.\n7. \\- Patients with a known allergy to any of the components of Ovosicare® Fertility.\n8. \\- Any other situation that, in the medical opinion, advises against treatment with Ovosicare® Fertility or that may make patient follow-up difficult.\n9. \\- Patients with suspected endometriosis.\n10. \\- Existence of fibroids affecting the endometrial cavity.\n11. \\- Patients with 2 or more previous abortions.\n12. \\- Patients with a current diagnosis of a high-risk human papillomavirus (HPV) cervical lesion.","32 Years","38 Years",{"count":56,"type":20},300,"The goal of this observational study is to evaluate whether supplementation with the Ovosicare® Fertility food supplement increases the possibility of becoming pregnant in women aged between 32 and 38 years who have been trying to become pregnant for at least 6 months before starting supplementation.",[59],"Fertility",[51,61,62,63],"Pregnancy","Food supplement","Ovosicare Fertility","2025-07-17",{"date":66,"type":36},"2025-07-24",{"date":68,"type":36},"2025-02-13",{"date":70,"type":20},"2026-12",{"name":42,"class":43},27,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100567424","a-multicenter-open-comparative-study-on-vaginal-dysbiosis-in-premenopausal-women-dispaloma-100567424","NCT06668012","A Multicenter, Open, Comparative Study on Vaginal Dysbiosis in Premenopausal Women (DISPALOMA)","A Multicenter, Open, Comparative Study on the Effect of Palomacare® Vaginal Gel on Vaginal Dysbiosis in Premenopausal Women (DISPALOMA)","DISPALOMA","Inclusion Criteria:\n\n1. Between 18 and 45 years of age, inclusive.\n2. Who are attending a gynecological visit for any reason and who are in the first phase of the menstrual cycle, between the end of menstruation and before ovulation (approximately between days 9 and 15).\n3. With regular menstrual cycles of between 24 and 35 days.\n4. Who are able to understand and sign the informed consent after the nature of the study has been fully explained to them.\n5. With a vaginal pH higher than 4.5 with or without symptoms\n\nExclusion Criteria:\n\n1. Diagnosis of another vaginal or vulvar condition that may confuse the interpretation of the response to the investigational product (erosive lichen planus, inflammatory desquamative vaginitis, or contact dermatitis involving the vulvar epithelium).\n2. Diagnosis of cervical intraepithelial neoplasia (CIN), cervical carcinoma, or endometrial neoplasia.\n3. Active genitourinary infections (VVC, N. gonorrhoeae, C. trachomatis, or T. vaginalis) at the time of inclusion or within 15 days prior to inclusion in the study.\n4. Active genital lesions (ulcers or vesicles compatible with herpes or warts) or genital bleeding.\n5. Pregnant patients or in the immediate postpartum period (up to 40 days).\n6. Contraception with copper IUD.\n7. Use of oral or topical antibiotics, or vaginal antifungals in the two weeks prior to the initial visit.\n8. Planned immunosuppressive therapy.\n9. Decompensated chronic diseases (diabetes, epilepsy, high blood pressure, etc.).\n10. Use of any other experimental drug or device during the 30 days prior to selection.\n11. Formal contraindication for the use of the product, such as hypersensitivity to any of the components of the study treatments.\n12. Inability, at the discretion of the researcher, to comply with the requirements of the study, either due to follow-up problems or due to psychophysical characteristics.","18 Years","45 Years",{"count":84,"type":20},30,"INTERVENTIONAL",[87],"NA","The hypothesis is raised of improving the status of vagnal microbiota with a non-hormonal topical product in early situations of dysbiosis in which the vaginal pH is elevated and the patient may or may not be symptomatic, in order to try to prevent the appearance of future established vaginal infections.",[90],"Vaginal Dysbiosis",[92,93,94],"Vaginal","Palomacare","Dysbiosis","2025-01-30",{"date":97,"type":36},"2025-02-03",{"date":99,"type":36},"2024-12-12",{"date":101,"type":20},"2025-05-31",{"name":42,"class":43},2,""]